J&J boosts prostate cancer R&D with $650 million deal, Medivation drops
This article was originally published in Scrip
Johnson & Johnson agreed to pay $650 million in cash for closely held Aragon Pharmaceuticals to get an experimental prostate cancer drug similar to Medivation's Xtandi.
You may also be interested in...
Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m.
VenBio has $315m in new cash to invest in a broad array of therapeutics developers now that it has closed its second venture capital fund, which raised $65m more than the VC firm originally intended and reflects big pharma's increasing commitment to backing early-stage life science companies.
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.